Drug Profile
Research programme: ZW 34 - Zymeworks
Alternative Names: Research programme: ZW-34 - ZymeworksLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Zymeworks
- Class Bispecific antibodies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lymphoblastic-leukaemia in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Canada